Sellas Life Sciences Group Inc
NASDAQ:SLS

  • LAST PRICE
    1.3200
  • TODAY'S CHANGE (%)
    0.0500 (3.9370%)
  • Bid / Lots
    1.3100/ 1
  • Ask / Lots
    1.3200/ 29
  • Open / Previous Close
    1.2800 / 1.2700
  • Day Range
    1.2500
    1.3495
  • 52 Week Range
    0.4986
    1.7200
  • Volume
    845,099

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 13, 2024

      Show headlines and story abstract

    • 4:15PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: SLS

    • 4:15PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: SLS

      SELLAS@lifesciadvisors.com
      SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share data) (Unaudited) Three Months Ended Nine Months Ended September September 30, 30, -------------------------- ---------------------------- 2024 2023 2024 2023 Operating expenses: Research and development $ 4,362 $ 5,813 $ 14,659 $ 18,910 General and administrative 2,967 3,548 9,936 10,782 ---------- ---------- ---------- ---------- Total operating expenses 7,329 9,361 24,595 29,692 ---------- ---------- ---------- ---------- Loss from operations (7,329) (9,361) (24,595) (29,692) Non-operating income: Change in fair value of warrant liability -- -- -- 4 Interest income 221 94 451 484 ---------- ---------- ---------- ---------- Total non-operating income 221 94 451 488 ---------- ---------- ---------- ---------- Net loss $ (7,108) $ (9,267) $ (24,144) $ (29,204) ========== ========== ========== ========== Per share information: Net loss per common share, basic and diluted $ (0.10) $ (0.33) $ (0.42) $ (1.09) ========== ========== ========== ========== Weighted-average common shares outstanding, basic and diluted 68,254,021 28,355,427 56,940,617 26,767,914 ========== ========== ========== ========== SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share data) (Unaudited) September 30, December 31, 2024 2023 --------------- ---------------- ASSETS Current assets: Cash and cash equivalents $ 21,031 $ 2,530 Restricted cash and cash equivalents 100 100 Prepaid expenses and other current assets 2,904 542 ---------- --------- Total current assets 24,035 3,172 Operating lease right-of-use assets 513 858 Goodwill 1,914 1,914 Deposits and other assets 43 275 ---------- --------- Total assets $ 26,505 $ 6,219 ========== ========= LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,547 $ 5,639 Accrued expenses and other current liabilities 5,490 7,650 Operating lease liabilities 576 446 ---------- --------- Total current liabilities 10,613 13,735 Operating lease liabilities, non-current -- 460 ---------- --------- Total liabilities 10,613 14,195 ---------- --------- Commitments and contingencies Stockholders' equity (deficit): Common stock, $0.0001 par value; 350,000,000 shares authorized, 64,381,979 and 32,132,890 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 6 3 Additional paid-in capital 257,274 209,265 Accumulated deficit (241,388) (217,244) ---------- --------- Total stockholders' equity (deficit) 15,892 (7,976) ---------- --------- Total liabilities and stockholders' equity (deficit) $ 26,505 $ 6,219 ========== =========

  • Nov 5, 2024

Peers Headlines